Antibodies to infliximab in patients with Crohn's disease do not cross-react with certolizumab pegol

被引：0
|
作者：
Vetterlein, O. [1 ]
Kopotsha, T. M. [1 ]
Nesbitt, A. M. [1 ]
Brown, D. T. [1 ]
Stephens, S. [1 ]
机构：
[1] Celltech Antibody Ctr Excellence, Antibody Biol Div, Slough, Berks, England
来源：
GUT | 2007年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
356
引用
收藏
页码：A116 / A116
页数：1
相关论文
共 50 条
  • [41] Certolizumab pegol is efficacious in Crohn's disease patients who have failed infliximab regardless of concomitant therapy or reason for failure
    Abreu, Maria
    Sandborn, William
    D'Haens, Geert
    Colombed, Jean-Frederic
    Mitchev, Krassimir
    Raedler, Andreas
    Lee, Scott
    Fedorak, Richard
    Vermeire, Severine
    Rutgeerts, Paul
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 : S430 - S431
  • [42] Improvement in Work Productivity and Daily Activities by Certolizumab Pegol in Crohn's Disease Patients with Prior Loss of Response or Intolerance to Infliximab
    Feagan, Brian
    Tan, Seng
    Brabant, Yves
    Wolf, Douglas
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 : S406 - S406
  • [43] Crohn's disease - infliximab, adalimumab and certolizumab-pegol: clinical value of anti-TNF-α treatment
    Schreiber, S.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2007, 132 (34-35) : 1770 - 1774
  • [44] Incidence of Anti-drug Antibodies in Crohn's Disease Patients During 5 Years of Certolizumab Pegol Therapy
    Sandborn, William
    Dubinsky, Marla
    Kosutic, Gordana
    Parker, Gerry
    Spearman, Marshall
    Hasan, Iram
    Coarse, Jason
    Ptak, Theodore
    Younes, Ziad
    Shafran, Ira
    Lee, Scott
    Afzali, Anita
    Khanna, Reena
    Feagan, Brian
    INFLAMMATORY BOWEL DISEASES, 2016, 22 : S41 - S41
  • [45] HOMOCITRULLINE ANTIBODIES CROSS-REACT WITH CITRULLINE
    Koivula, M-K
    Turunen, S.
    Risteli, L.
    Karjalainen, A.
    Hakala, M.
    Risteli, J.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2010, 39 (05) : 446 - 446
  • [46] Mucosal Healing in Patients Receiving Certolizumab Pegol for Crohn's Disease (CHARTER Study)
    Randall, Charles
    Herrera, Christian
    Taboada, Carlo
    Fincke, Christopher
    Havranek, Russell
    Zurita, Franz
    Stump, David
    Gossen, Gary
    Vidaurri, Daniela
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 : S436 - S437
  • [47] CIMZIA (Certolizumab Pegol) is effective in the treatment of Crohn's Disease patients with open fistulas
    Schreiber, S.
    Lawranc, I
    Thomsen, O.
    Hanauer, S.
    Bloomfield, R.
    Sandborn, W.
    INFLAMMATORY BOWEL DISEASES, 2008, 14 (12) : S1 - S1
  • [48] CERTOLIZUMAB PEGOL IN PATIENTS WITH CROHN'S DISEASE: A LONG TERM UPDATE OF COMPASSIONATE USE
    Mocciaro, F.
    Renna, S.
    Orlando, A.
    Olivo, M.
    Sinagra, E.
    Cottone, M.
    DIGESTIVE AND LIVER DISEASE, 2011, 43 : S189 - S189
  • [49] Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab
    Feagan, B. G.
    Sandborn, W. J.
    Wolf, D. C.
    Coteur, G.
    Purcaru, O.
    Brabant, Y.
    Rutgeerts, P. J.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 33 (05) : 541 - 550
  • [50] Certolizumab Pegol Treatment Impacts Hospitalizations and Surgeries in Crohn's Disease Patients with Prior Failure to Infliximab: Results From WELCOME Trial
    Feagan, Brian
    Tan, Seng
    Brabant, Yves
    Wolf, Douglas
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 : S406 - S406
12345